Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

Inhibitors of Lysyl Oxidase for the Prevention and Treatment of Invasive and Metastatic Cancer (360G-Wellcome-103021_Z_13_A)

The enzyme lysyl oxidase (LOX) regulates cross-linking of structural proteins in the extracellular matrix. LOX also plays a role in stimulating the metastatic spread of cancer through the body. Its expression is increased in hypoxic cancers and is correlated with tumour metastasis and decreased patient survival. In model systems its inhibition significantly decreases cancer metastasis and increases survival. Since metastasis is responsible for over 90 per cent of cancer deaths these data validate LOX as an important therapeutic target in cancer. Professor Caroline Springer and Professor Richard Marais from the Institute of Cancer Research have been awarded Seeding Drug Discovery funding to develop drugs that target LOX. They are applying a medicinal chemistry drug discovery approach underpinned by a strong programme in LOX biology with the aim of producing orally available, small molecular weight drugs that inhibit LOX activity for cancer treatment.


02 Oct 2016

Grant details
Amount Awarded 402800
Applicant Surname Springer
Approval Committee Seeding Drug Discovery Committee
Award Date 2016-10-02T00:00:00+00:00
Financial Year 2016/17
Grant Programme: Title Seeding Drug Discovery Award
Internal ID 103021/Z/13/A
Lead Applicant Prof Caroline Springer
Planned Dates: End Date 2017-07-31T00:00:00+00:00
Planned Dates: Start Date 2016-02-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Greater London
Additional data added by GrantNav